| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
46.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.57 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
49,815 |
194,004 |
265,777 |
1,488,473 |
| Total Sell Value |
$38,529 |
$137,285 |
$313,570 |
$9,885,249 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
39 |
62 |
109 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-10-20 |
4 |
S |
$1.54 |
$550 |
D/D |
(357) |
126,238 |
|
50% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-10-20 |
4 |
S |
$1.54 |
$2,273 |
D/D |
(1,475) |
1,170,239 |
|
50% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-10-19 |
4 |
S |
$1.58 |
$13,558 |
D/D |
(8,581) |
881,977 |
|
53% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-10-19 |
4 |
S |
$1.58 |
$566 |
D/D |
(358) |
126,595 |
|
53% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-10-19 |
4 |
S |
$1.58 |
$1,947 |
D/D |
(1,232) |
1,171,714 |
|
53% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-10-03 |
4 |
S |
$1.98 |
$1,492 |
D/D |
(755) |
1,172,946 |
|
66% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-10-03 |
4 |
S |
$1.98 |
$2,619 |
D/D |
(1,325) |
890,558 |
|
66% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-10-03 |
4 |
S |
$1.98 |
$439 |
D/D |
(222) |
126,953 |
|
66% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-08-18 |
4 |
S |
$2.79 |
$11,313 |
D/D |
(4,055) |
891,883 |
|
75% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-08-17 |
4 |
S |
$2.50 |
$26,243 |
D/D |
(10,516) |
1,173,701 |
|
70% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-08-17 |
4 |
S |
$2.50 |
$28,351 |
D/D |
(11,361) |
895,938 |
|
70% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-08-17 |
4 |
S |
$2.50 |
$4,125 |
D/D |
(1,653) |
127,175 |
|
70% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-07-20 |
4 |
S |
$3.35 |
$4,810 |
D/D |
(1,437) |
1,184,217 |
|
53% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-07-20 |
4 |
S |
$3.35 |
$1,145 |
D/D |
(342) |
128,828 |
|
53% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-07-19 |
4 |
S |
$3.56 |
$4,267 |
D/D |
(1,198) |
1,185,654 |
|
54% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-07-19 |
4 |
S |
$3.56 |
$1,218 |
D/D |
(342) |
129,170 |
|
54% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-07-19 |
4 |
S |
$3.56 |
$29,710 |
D/D |
(8,342) |
907,299 |
|
54% |
|
| Sinha Vikas |
See Remarks |
• • • |
2023-07-05 |
4 |
S |
$3.05 |
$9,084 |
D/D |
(2,983) |
1,186,852 |
|
56% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-07-05 |
4 |
S |
$3.05 |
$16,063 |
D/D |
(5,275) |
915,641 |
|
56% |
|
| Piccina Cintia |
Chief Commercial Officer |
• – – |
2023-07-03 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
147,000 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2023-06-27 |
4 |
B |
$3.75 |
$10,990,763 |
D/D |
2,930,870 |
16,635,286 |
2.45 |
-45% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2023-06-09 |
4 |
AS |
$5.64 |
$28,453 |
D/D |
(5,045) |
129,512 |
|
-70% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2023-05-18 |
4 |
S |
$4.21 |
$19,115 |
D/D |
(4,536) |
916,628 |
|
46% |
|
| Brenner Malcolm |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
65,197 |
|
- |
|
| Jovan-Embiricos Morana |
Director |
– • • |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
65,197 |
|
- |
|
304 Records found
|
|
Page 3 of 13 |
|
|
